The psoriasis biologics market is gradually moving from single-target competition toward more differentiated mechanism-based competition. In August 2026, information published on the official website of NMPA showed that lecankitug injection was approved for marketing for adults with moderate-to-severe plaque psoriasis…
On August 27, Johnson & Johnson announced that Icotrokinra had been approved by NMPA for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, as well as pediatric patients aged 12 years and…
Recibokibart approved for GPP marks a major milestone in Generalized Pustular Psoriasis (GPP) treatment. Developed by Shanghai Huaota Biopharmaceutical Co., Ltd., this IL-36R monoclonal antibody was approved by the NMPA on July 29, 2026, for adult patients with acute GPP…
On June 11, Akeso announced that its self-developed IL-17A monoclonal antibody, Gumokimab (AK111, brand name Qiyoukang®), received approval from China’s National Medical Products Administration (NMPA) for the treatment of adults with moderate-to-severe plaque psoriasis. The approval of Gumokimab for plaque…
Generic Name/Brand Name: Gumokimab/Qiyoukang Indications: Moderate-to-severe plaque psoriasis in adults Dosage Form: Injection (subcutaneous) Specification: 150 mg/1 prefilled pen per box
Biologic therapies have fundamentally changed how chronic inflammatory diseases are treated, shifting the focus from broad immunosuppression to targeted immune modulation. From this evolving therapeutic landscape, DengYue Medicine has closely followed the emergence of next-generation biologics that redefine standards of…
Generic Name/Brand Name: Ixekizumab/Taltz Indications: Plaque Psoriasis Dosage Form: Injection Specification: 80mg/ml x 1 syringe
🤔 When well-defined red patches covered in silvery-white scales appear on the skin, it is often more than just a cosmetic concern—it reflects a “microscopic war” being waged on the skin’s surface. Plaque psoriasis is a chronic immune-mediated inflammatory skin…
Generic Name/Brand Name: Risankizumab/Skyrizi Indications: Psoriasis Dosage Form: Injection Specification: 150 mg × 1 syringe & 600 mg × 1 vial
Generic Name/Brand Name: Tildrakizumab/ILUMETRI Indications: Tlaque Psoriasis Dosage Form: Solution for subcutaneous injection Specification: 100 mg / 1 mL * 1 vial
